广东基孔肯雅热病例数累计逾七千例，缘何药企研发疫苗积极性不高

Core Insights - There is currently no available vaccine for Chikungunya virus in China, with over 7,000 reported local cases in Guangdong province as of August 9, 2025 [1] - The lack of vaccine development is attributed to limited market potential, high development costs, and competition concerns [2][3] Group 1: Vaccine Development Challenges - The cost of developing a vaccine is significant, with preclinical and early clinical phases costing approximately 30 million yuan each, and late-stage clinical trials potentially exceeding 100 million yuan [2] - The economic value of developing a Chikungunya vaccine is considered limited due to the disease's transmission being reliant on mosquito vectors, which are primarily found in tropical and subtropical regions [2] - The current model of "imported cases leading to local transmission" results in annual incidence numbers that are much lower than more common infectious diseases like influenza and hepatitis B, leading to concerns about market viability for new vaccines [2][3] Group 2: Market and Strategic Considerations - Traditional vaccine development timelines can take five to seven years, during which time the market may be dominated by imported vaccines or emergency imports, creating uncertainty for domestic developers [3] - The clinical trials for vaccines require thousands of participants and must be conducted in tropical and subtropical areas, adding to the complexity and cost of development [3] - Companies are more likely to allocate resources to vaccines with higher return on investment unless there is a clear national strategic reserve need or limitations on imported vaccines [3] Group 3: Prevention Measures - Current prevention strategies focus on mosquito control, including eliminating breeding sites and using repellents and mosquito nets [3]